Justin Hobson made a guest appearance on episode #6 of CFN Insider’s “Profit From Cannabis” podcast. The episode, entitled “The US Cannabis Marker: New Promise, Persistent Constraints,” covers:
- The FDA’s approval of GW Pharma’s Epidiolex,
- Impact of rescheduling cannabis and DEA’s rescheduling possibilities (isolate vs. cannabis plant),
- Resulting investment plays (cannabinoid drug developers, hemp extracts), and
- A legalization roundtable that discussed how state cannabis programs are faring under the Trump Administration.
Hobson commented on the growing risks investors’ face since the rescission of the Cole Memo, the increased scrutiny that applicants have observed from the Oregon Liquor Control Commission, and the industry’s problem with product diversion. Have a listen!